According to a study conducted at the LSU Health New Orleans Center of Neuroscience of Excellence, the combination of LSU Health’s patented drug and selected DHA derivatives provides better brain cell protection and post-stroke recovery than a single drug. Effective for increasing.
Discovered by Dr. Nicholas Bazan, MD, Professor of Neurology, Professor of Neurology, Director of Neuroscience Center of Excellence, LSU Health New Orleans School of Medicine, Dr. Ludmila Bellaev, Professor of Neuroscience, Neurology, Neurosurgery, LSU Health This new treatment strategy for ischemic stroke.
During an ischemic stroke, signals are generated from white blood cells that arrive in the blood and primary brain immune cells called microglia, which cause neuroinflammation and the accumulation of chemicals that are harmful to the brain. Platelet activating factor (PAF) accumulates and inhibition of this process plays an important role in neuronal survival. In addition to its anti-inflammatory properties, Dr. Bazan’s early work stimulated the production of neuroprotectin D1 (NPD1), an essential omega-3 fatty acid that protects brain cells and promotes their survival. It was also shown to do. One of the complex factors in developing a neuroprotective strategy for stroke is the multiple pathways and events that occur in the brain during stroke. This has been approached primarily by monotherapy with little success.
Since no single effective treatment for the complexity of stroke has been proven, the team aimed for two different events-inflammation-induced platelet-activating factor receptor (PAF-R) blockade and Activation of the cell survival pathway. Treatment with LAU-0901, a synthetic molecule found at the Bazan Institute that blocks pro-inflammatory platelet activating factor, and aspirin-induced NPD1 (AT-NPD1) reduced the size of the damaged area of the brain. The mechanism that we found to have initiated repair, and significantly improved behavioral recovery.
Total lesion volume decreased by 62% with LAU-0901 and NPD1 and 90% with LAU-0901 and AT-NPD1. The combination of LAU-0901 and AT-NPD1 improved behavioral scores by up to 54% on day 3. LAU-0901 and LAU-0901 and DHA reduced the production of the pro-inflammatory mediator 12-hydroxyeicosatetraenoic acid.
“The biological activity of LAU-0901 and AT-NPD1 is due to the specific activation or regulation of signaling pathways associated with the immune system, inflammation, cell survival, and cell-cell interactions,” said Dr. Bazan. I will. “These findings provide key conceptual advances in cell survival, brain function, and a wide range of therapeutic relevance, especially for stroke and neurodegenerative diseases.”
“We have discovered that these new molecules promote the survival of nerve cells with important anti-inflammatory effects,” explains Dr. Belayev. “This combination therapy has the potential to be promising for the development of future treatments for ischemic stroke.”
According to the US Centers for Disease Control and Prevention, someone in the United States has a stroke every 40 seconds. Every four minutes, someone dies of a stroke. Each year, more than 795,000 people in the United States have a stroke. Approximately 87% of all strokes are ischemic strokes, blocking blood flow to the brain. Stroke-related costs in the United States reached nearly $ 46 billion between 2014 and 2015. This total includes medical services, medications to treat stroke, and days absent. Stroke is a major cause of serious long-term disability. Stroke reduces mobility in more than half of stroke survivors over the age of 65.
Other LSU Health authors include PhD. Pranab K. Mukherjee, Eric J. Knott, Reinaldo B. Oria, Larissa Khoutorova, graduate students Madigan M. Reid and Cassia R. Roque. Co-authors are Dr. Andre Obenaus, Dr. Lawrence Nguyen, Dr. John Bin Lee, University of California, Irvine Medical College, and Dr. Nicos A. Petasis, University of Southern California.
The study was supported by strokes from the National Institutes of Neurology and Health and grants from CAPES in Brazil.